A majority of people saw tumor shrinkage with ROZLYTREK™

ROZLYTREK was studied in 51 people with ROS1+ mNSCLC across 3 clinical trials. These studies measured 2 things: how many people had their tumors shrink, and the length of time that response lasted. The trials did not compare ROZLYTREK to another medication.

  • 70% (28 out of 40 people) had a response continue to at least 9 months
  • 55% (22 out of 40 people) had a response continue to at least 12 months
  • 30% (12 out of 40 people) had a response continue to at least 18 months

ROZLYTREK was shown to reduce cancer that had spread to the brain

In the same clinical trials, 7 of 51 people had ROS1+ mNSCLC that had spread to the brain (known as CNS metastases) and did not have prior radiation therapy for these tumors (within 2 months of starting ROZLYTREK).

*It is important to know that tumor shrinkage does not mean the cancer has been cured.
CNS=central nervous system.

Financial Resources

Financial and other resources

Learn about financial and other resources to help you access ROZLYTREK™.

Getting ROZLYTREK

Getting ROZLYTREK

Learn about specialty pharmacy options.